PGY2 Program
Residency Program Director
-
Brianna Archambeau, PharmD, BCOP
- PGY2 Oncology Residency Program Director, The James Cancer Hospital at The Ohio State University
- PGY2 Oncology, Karmanos Cancer Center, Detroit, Michigan
- PGY1, University of Toledo Medical Center, Toledo, Ohio
- PharmD, Univeristy of Toledo
Previous Year Residents
-
2025
Delvin Omer, PharmD
Outpatient Lymphoma/Inpatient Hematology Clinical Pharmacy Specialist, Atrium Health Wake Forest Baptist Medical Center, Winston Salem, NC -
Kennedi Satterfield, PharmD
Bone Marrow Transplant Clinical Specialist Pharmacist, The James OSUWMC -
Adithya Ghantae, PharmD
Outpatient Clinical Oncology Pharmacist, Novant Health, Mooresville, NC -
Nicole Gula, PharmD
Inpatient Hematology/Oncology Pharmacy Specialist, The James OSUWMC -
Victoria Yosick, PharmD
Inpatient/Outpatient Lymphoma & Myeloma Pharmacy Float, The James OSUWMC -
2024
Zachary Arnold, PharmD
Hematology/Oncology Specialty Practice Pharmacy Float-The James OSUWMC -
Courtney Krall, PharmD, MPH
Outpatient Hematology/Oncology Clinical Pharmacy Specialist-The James OSUWMC -
Nathan Lamb, PharmD, BCPS
Clinical Pharmacy Specialist-BMT/Cellular Therapy-Moffitt Cancer Center-Tampa, FL -
Nilmarie Ayala Fontanez, PharmD, MS
Inpatient/Outpatient Hematology/Oncology Float Specialist-The James OSUWMC -
2023
Jasmine Browning, PharmD
Hematology/Oncology Clinical Pharmacist, University of Louisville Hospital Brown Cancer Center -
Tyler Smith, PharmD
Hematology/Oncology Pharmacist Specialist at The James Cancer Hospital
About the PGY2 Oncology Residency Program
Residency Sites
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care — a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only a few centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs sponsored by the NCI. As the cancer program’s 356-bed adult patient-care component, The James is one of the top
cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet® designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care.
The center includes six outpatient chemotherapy infusion clinics, dispensing an estimate of over 75,000 doses of chemotherapy annually. The Department of Pharmacy consists of inpatient and outpatient hematology/oncology clinical
specialist pharmacists, pain and palliative medicine pharmacists, anti-coagulation pharmacists, cancer informatics pharmacists, medication assistance pharmacists, and Hematology/Oncology specialty practice pharmacy residents.
The James Cancer Hospital at The Ohio State University offers a one-year postgraduate year two (PGY2) ASHP accredited oncology pharmacy residency program. The clinical pharmacy program is designed to align with our sub-specialized disease specific model allowing residents the opportunity to train with clinical specialists who are experts in their sub-specialty in both inpatient and ambulatory clinic setting. The program allows residents to develop their hematology/oncology knowledge base including cancer treatment, supportive care, and the role of clinical trials in this patient population. Upon completion of the program, the resident will have the skill set necessary to work as a respected member of a multi-disciplinary hematology/oncology patient care team.
KEY ROTATIONS/EXPERIENCES
The resident will complete a combination of rotations and longitudinal experiences designed around the core objectives specified by ASHP in addition to the resident’s interest.
Orientation: 4 weeks (orientation may be modified for early commit residents)
Research: 3-4 weeks
Hematology
- Inpatient Acute Leukemia – 4 weeks
- Bone Marrow Transplantation – 5 weeks
- Inpatient Lymphoma – 4 weeks
- Outpatient Hematology Clinics (Chronic Leukemias, Multiple Myeloma, & lymphoma) – 3 weeks
Oncology
- Inpatient Oncology – 4 weeks
- Outpatient Solid Tumor Clinics
- Outpatient Breast Cancer – 3 weeks
- Outpatient Gastrointestinal Cancers (GI) + Melanoma – 4 weeks
- Outpatient Lung (thoracic) – 3 weeks
- Outpatient Genitourinary (GU) – 3 weeks
- Outpatient Gynecology Oncology – 1 week
Clinical Trials Unit (CTU): 1 week
Pain and Palliative: 1 week
Administration: 1 week
- Required Longitudinal
- Medication Safety
- Teaching
- Research/MUE
Electives: 4-8 weeks, experiences can be 1-4 weeks in length, electives not listed below can be arranged on specific request
- Anything in required repeated
- Inpatient Leukemia
- Inpatient Benign Heme
- Inpatient Gynecology
- Inpatient Multiple Myeloma
- Outpatient BMT
- Outpatient Head & Neck
- Outpatient Leukemia
- Outpatient Sarcoma
- Outpatient Neuro-oncology
- Oncology Academia
- Oncology Administration
- Informatics
- Infectious Diseases
- Pediatric Hematology/Oncology (Nationwide Children’s Hospital)
Selected RESIDENT RESEARCH
- Comparison of Toxicity Rates of Reduced Dose Pegaspargase versus Full Dose Pegaspargase in Adults with Acute Lymphoblastic Leukemia. Ghantae, Adithya
- Trastuzumab deruxtecan (Enhertu) efficacy and safety in GYN malignancies: a single academic medical center experience Gula, Nicole
- Impact of Predicted Fludarabine Exposure on Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplant Omer, Delvin
- Pathological complete response rates compared between carboplatin dosing schedules in modified Keynote-522 regimen with dose-dense doxorubicin and cyclophosphamide for early-stage breast cancer Satterfield, Kennedi
- Real-world evaluation of gemcitabine, cisplatin, and durvalumab with a modified biweekly schedule used in the treatment of patients with advanced biliary tract cancer Yosick, Victoria
Benefits and Additional Requirements
Application Deadline:
January 2
We welcome applications from non-U.S. citizens who have a “green card” (permanent resident status) or a current visa valid through the entire duration of the residency program. The Ohio State University pharmacy residency programs are NOT able to sponsor visas for pharmacy residents (PGY1 or PGY2).
Start Date: July 1
Annual Salary – $56,000
Vacation Days – 10 Days
Staffing Requirement – 19 weekends per year
Completion of a Major Research Project
